UiPath
PATH
$10.16
-1.07%
UiPath, Inc. is a leading provider of an end-to-end enterprise automation platform, operating within the Software - Infrastructure industry. The company is a market leader in Robotic Process Automation (RPA), distinguished by its cross-application platform that leverages computer vision, UI automations, and artificial intelligence to automate repetitive tasks across various business functions. The current investor narrative is sharply focused on whether the company can successfully transition from its core RPA roots to capitalize on the emerging 'agentic AI' orchestration market, with recent news highlighting a surge in optimism after strong quarterly results and a raised outlook, juxtaposed against ongoing debates about potential existential competition from generative AI.…
PATH
UiPath
$10.16
Related headlines
Investment Opinion: Should I buy PATH Today?
Rating & Thesis: Hold. PATH presents a compelling but high-risk turnaround story where strong recent fundamentals are overshadowed by severe technical damage and an existential competitive narrative, resulting in a neutral risk/reward profile at the current price. The limited analyst coverage showing neutral ratings (Market Perform, Equal Weight) supports a cautious stance.
Supporting Evidence: The hold rating is supported by four key data points: 1) The attractive forward P/E of 11.3x suggests limited downside if profitability holds, 2) Robust 13.56% revenue growth and 84.88% gross margins indicate a healthy core business, 3) Exceptional free cash flow generation of $352.2M TTM and a fortress balance sheet significantly de-risk the equity, and 4) The stock trades near the low end of its own historical valuation range (trailing P/E of 24.0x vs. past highs near 994x), suggesting much of the pessimism is priced in.
Risks & Conditions: The two biggest risks are the generative AI competitive threat and the volatility of quarterly earnings. This Hold would upgrade to a Buy if the stock sustains a break above key technical resistance (e.g., the $13-$14 area) on confirmation of consistent profitability (e.g., two more quarters of positive net income) and provides clear evidence of successful agentic AI product adoption. It would downgrade to a Sell if revenue growth decelerates below 10% or if the stock breaks decisively below its 52-week low of $9.2. The stock is currently fairly valued relative to its near-term earnings potential but carries a significant discount due to long-term structural risks.
Sign up to view all
PATH 12-Month Price Forecast
The AI assessment is neutral based on a clash between strong underlying financials and powerful negative market narratives. The company's high cash flow and reasonable forward valuation create a floor, but the technical downtrend and existential competitive threat create a ceiling. The most likely path is a continued basing period (base case, 55% probability) as the market waits for conclusive evidence on the AI transition. The stance would upgrade to bullish on a sustained breakout above $14 with volume, confirming a narrative shift. It would turn bearish on a breakdown below $9.2, signaling the fundamental story is deteriorating.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on UiPath's 12-month outlook, with a consensus price target around $13.21 and implied upside of +30.0% versus the current price.
Average Target
$13.21
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$8 - $13
Analyst target range
Analyst coverage for UiPath appears limited, with only 5 analysts providing estimates for future EPS and revenue, and no consensus price target or recommendation data provided in the dataset. This indicates insufficient analyst coverage is available for a detailed consensus view. The implications are significant: limited coverage is typical for a mid-cap company like UiPath and can lead to higher volatility and less efficient price discovery, as the stock is less scrutinized by institutional research. The available institutional ratings from recent months show a pattern of stability, with firms like BMO Capital, Morgan Stanley, and Wells Fargo maintaining 'Market Perform', 'Equal Weight', and 'Equal Weight' ratings respectively in March 2026, suggesting a neutral to cautious stance among those who do cover it, with no widespread downgrades or upgrades evident in the provided data.
Bulls vs Bears: PATH Investment Factors
The bull case for PATH is grounded in its strong fundamentals: recent profitability, exceptional cash generation, an attractive forward valuation, and a strategic pivot into agentic AI. The bear case is equally compelling, driven by a severe technical breakdown, volatile earnings, and an existential competitive threat from generative AI. Currently, the bearish evidence appears stronger, as the stock's price action near 52-week lows reflects deep skepticism that the strong Q1 results can be sustained or that the company can successfully navigate the AI transition. The single most important tension in the investment debate is whether PATH's RPA platform is a durable foundation for the agentic AI future or an obsolete technology being disrupted by generative AI. The resolution of this narrative will likely dictate the stock's direction more than near-term financial metrics.
Bullish
- Strong Profitability & Cash Flow: The company generated $104.5M in net income last quarter with a robust 21.7% net margin, demonstrating a significant shift towards profitability. This is supported by $352.2M in trailing free cash flow and $871.6M in cash on hand, providing a fortress balance sheet with a debt-to-equity ratio of just 0.039.
- Attractive Forward Valuation: PATH trades at a forward P/E of 11.3x, which is a steep discount to its trailing P/E of 24.0x, implying the market expects substantial earnings growth. This forward multiple is also near the low end of its own historical valuation range, suggesting a potential value opportunity if profitability is sustained.
- High-Growth, High-Margin Business Model: UiPath maintains a premium software gross margin of 84.88% and delivered 13.56% YoY revenue growth last quarter. This combination of growth and high margins is characteristic of a scalable platform business with strong pricing power.
- Strategic Position in Agentic AI: Recent news highlights the company's potential to transition from core RPA to the emerging 'agentic AI' orchestration market. This narrative, coupled with a recent stock surge after strong Q1 results and a raised outlook, provides a catalyst for a growth re-rating if execution continues.
Bearish
- Severe Technical Downtrend & Underperformance: The stock is down 36.29% over 6 months and trades just 11.7% above its 52-week low of $9.2, reflecting deep bearish sentiment. It has shown a -41.97% relative strength vs. the SPY over the past year, indicating severe company-specific concerns outweighing its market-neutral beta of 0.968.
- Volatile & Inconsistent Profitability: Despite a strong last quarter, PATH reported a net loss of $22.6M in Q1 2026, highlighting earnings volatility. The operating margin is thin at 3.78%, indicating high spending that could pressure profits if revenue growth decelerates.
- Existential Competitive Threat from GenAI: A key bear narrative, highlighted in recent news, is that generative AI could disrupt or permanently impair UiPath's core RPA value proposition. This creates a long-term uncertainty overhang that is difficult to quantify but weighs on investor sentiment and the growth multiple.
- Limited Analyst Coverage & Neutral Sentiment: Only 5 analysts provide estimates, and available institutional ratings (e.g., Market Perform, Equal Weight) suggest a neutral-to-cautious stance. Limited coverage can lead to higher volatility and less efficient price discovery, potentially delaying a positive re-rating.
PATH Technical Analysis
The stock is entrenched in a pronounced downtrend, with a 1-year price change of -16.98% and a more severe 6-month decline of -36.29%. The current price of $10.27 (as of the latest close) sits just 11.7% above its 52-week low of $9.2, positioning it near the bottom of its annual range, which typically signals a value opportunity but also reflects deep-seated bearish sentiment and fundamental concerns. Recent momentum shows a slight deceleration from the longer-term downtrend, with a 1-month change of -2.65% and a 3-month change of -14.84%, indicating the selling pressure has moderated but the stock has failed to mount a meaningful recovery. The stock's beta of 0.968 suggests its volatility is nearly in line with the broader market, yet its severe underperformance is stark, evidenced by a 1-year relative strength of -41.97% against the SPY. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $19.84 and critical support at the $9.2 low. A sustained breakdown below $9.2 would signal a potential acceleration of the downtrend, while any recovery would first need to contend with overhead resistance built up over months of decline, with the stock's low beta indicating moves may be more driven by company-specific news than broad market swings.
Beta
0.97
0.97x market volatility
Max Drawdown
-51.4%
Largest decline past year
52-Week Range
$9-$20
Price range past year
Annual Return
-16.6%
Cumulative gain past year
| Period | PATH Return | S&P 500 |
|---|---|---|
| 1m | -7.0% | -0.2% |
| 3m | -8.2% | +14.0% |
| 6m | -40.8% | +7.8% |
| 1y | -16.6% | +25.3% |
| ytd | -36.0% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PATH Fundamental Analysis
UiPath's revenue trajectory shows consistent growth, with the most recent quarterly revenue of $481.1 million representing a 13.56% year-over-year increase. Segment data reveals the business is primarily driven by Subscription Services ($251.2M) and License revenue ($215.9M), indicating a strong shift towards recurring software models. However, profitability has been volatile; the company reported net income of $104.5 million for the latest quarter with a robust net margin of 21.7%, but this follows a net loss of $22.6 million in the prior quarter (Q1 2026), highlighting inconsistency. The gross margin remains exceptionally high at 84.88%, typical for a software company, but operating margins are thin at 3.78%, pointing to significant spending on sales and R&D. The balance sheet and cash flow position is a clear strength, with a very healthy current ratio of 2.48, minimal debt (debt-to-equity of 0.039), and strong free cash flow generation of $352.2 million on a TTM basis. This substantial cash generation, coupled with $871.6 million in cash on hand, provides ample liquidity to fund operations and strategic investments without reliance on external financing, significantly de-risking the equity story despite operational volatility.
Quarterly Revenue
$481107000.0B
2026-01
Revenue YoY Growth
+0.13%
YoY Comparison
Gross Margin
+0.84%
Latest Quarter
Free Cash Flow
$352160000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PATH Overvalued?
Given UiPath's positive net income of $104.5 million in its latest quarter, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 24.0x and a forward PE of 11.3x; the significant gap implies the market expects a substantial near-term earnings acceleration, likely pricing in the company's path to sustained profitability. Compared to industry averages, specific data is not available in the provided dataset for a direct sector PE comparison, limiting a precise premium/discount assessment. Historically, the current trailing PE of 24.0x is below the stock's own historical range observed in recent quarters, which has seen figures as high as 994x during periods of minimal earnings and as low as 10.7x. Trading near the lower end of its own historical band suggests the market is pricing in either a value opportunity or continued skepticism about the durability of its recent profitability, rather than optimistic growth expectations.
PE
24.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -163x~994x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
50.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: UiPath's primary financial risk is the volatility of its profitability, as evidenced by swinging from a $22.6M loss in Q1 2026 to a $104.5M profit in the latest quarter. This inconsistency raises questions about the sustainability of its 21.7% net margin. Furthermore, while revenue grew 13.56% YoY, this growth rate must be maintained to justify even its modest forward P/E of 11.3x, as deceleration could trigger multiple compression. The company's high operating expenses, resulting in a thin 3.78% operating margin, leave little room for error if competitive or sales execution pressures emerge.
Market & Competitive Risks: The paramount market risk is the potential for generative AI to directly compete with or make obsolete UiPath's core RPA automation tasks. This existential threat, frequently cited in news, creates a persistent overhang on the stock's valuation multiple. From a valuation perspective, while the forward P/E appears cheap, the stock trades at a PS ratio of 4.2x and an EV/EBITDA of 50.9x, which are elevated for a company with mid-teens growth, indicating vulnerability to sector-wide de-rating of software stocks. Its market-neutral beta of 0.968 offers little defensive protection in a broad market sell-off.
Worst-Case Scenario: The worst-case scenario involves PATH failing to articulate a credible defense against generative AI competition, leading to a rapid deceleration in revenue growth below 10% while operating expenses remain high. This would crush its thin operating margin, return it to consistent losses, and invalidate the forward earnings growth priced into its 11.3x P/E. In this adverse scenario, the stock could re-test and break its 52-week low of $9.2, representing a downside of approximately -10% from the current $10.27 price. A more severe bear case, factoring in a full competitive disruption, could see the stock fall towards its historical max drawdown level of -51%, implying a price in the $5-$6 range.
FAQ
The key risks, in order of severity, are: 1) Competitive/Existential Risk: Generative AI could directly compete with or make obsolete UiPath's core RPA solutions, a narrative heavily cited in recent news. 2) Execution/Financial Risk: Profitability is volatile (from a $22.6M loss to a $104.5M profit in consecutive quarters), and the thin 3.78% operating margin leaves little room for error. 3) Sentiment/Technical Risk: The stock is in a severe downtrend, down 36% in 6 months and underperforming the SPY by 42% over one year, which can become a self-fulfilling prophecy. 4) Liquidity/Coverage Risk: With only 5 analysts providing estimates, the stock suffers from lower institutional scrutiny and potentially higher volatility.
The 12-month forecast for PATH is a range-bound outcome with a skew to the upside if catalysts materialize. The base case (55% probability) sees the stock trading between $11 and $14 as growth stabilizes but the AI overhang persists. The bull case (25% probability) targets $16 to $19 on successful execution of its agentic AI strategy and sustained profitability. The bear case (20% probability) warns of a drop to $8-$10 if growth decelerates and competitive fears intensify. The most likely scenario is the base case, predicated on the assumption that the company executes steadily but fails to completely resolve the market's long-term doubts within the next year.
PATH appears fairly valued to slightly undervalued based on near-term earnings, but this discounts significant long-term risk. Its forward P/E of 11.3x is low for a software company with 13.6% growth and 84.9% gross margins, suggesting undervaluation. However, its elevated EV/EBITDA of 50.9x and PS ratio of 4.2x reflect the market's skepticism about future growth durability. Compared to its own history, trading at a trailing P/E of 24.0x is near the low end of its range. The valuation implies the market expects mid-teens growth but assigns a high probability to competitive disruption, creating a risk premium that depresses the multiple.
PATH is a high-risk, high-potential-reward stock that may be a good buy for specific investors. For risk-tolerant investors who believe the generative AI threat is overblown and that UiPath can successfully pivot to agentic AI, the current valuation (11.3x forward P/E) and strong cash flow ($352M TTM) present an attractive entry point. However, given its severe 36% six-month decline and proximity to 52-week lows, it is not a good buy for conservative investors or those with a short time horizon. The investment requires patience and a high conviction in management's ability to navigate a competitive transition.
PATH is suitable only for long-term investment with a minimum horizon of 2-3 years. The stock's high volatility (evident in its 51% max drawdown), lack of dividend, and unresolved strategic narrative make it a poor candidate for short-term trading. A long-term horizon is required to see through quarterly earnings volatility and allow the company's agentic AI transition to play out, which is the central thesis for any substantial upside. Given its market-neutral beta of 0.97, its price movements will be more tied to company-specific execution than broad market trends, further emphasizing the need for a patient, long-term view.